story of the week
Efficacy and Safety of Trastuzumab Deruxtecan vs Treatment of Physician's Choice in Patients With HER2-Positive Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
Lancet 2023 May 27;401(10390)1773-1785, F André, Y Hee Park, SB Kim, T Takano, SA Im, G Borges, JP Lima, S Aksoy, J Gavila Gregori, M De Laurentiis, G Bianchini, R Roylance, Y Miyoshi, A Armstrong, R Sinha, M Ruiz Borrego, E Lim, J Ettl, R Yerushalmi, F Zagouri, FP Duhoux, T Fehm, D Gambhire, J Cathcart, C Wu, C Chu, A Egorov, I KropFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.